Fewer circulating CD4+PD‐L1+ and CD8+PD‐L1+ T cells correlate with improved progression‐free survival in patients with renal cell carcinoma receiving immune checkpoint inhibitors [21]. The gene discussed is CD274; the disease is hereditary clear cell renal cell carcinoma.